HAE · NYSE · Health Care Supplies
Health Care Supplies company based in Boston, Massachusetts.
In the last 90 days, no insider of Haemonetics reported an open-market purchase and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$104.68
Last 12 months
Not enough history
Market value
$4.76B
Revenue
$339M
+5.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$291M
This quarter $44.4M, a year earlier $13.6M
Net debt
$965M
Debt $1.19B, cash $223M, at Jun 27, 2026
Backlog
$31M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2026
$1.33B
−2.0% vs the year before
Net income, fiscal 2026
$97.3M
As reported in the annual filing
Shares outstanding
45.5M
As of Jul 31, 2026
In fiscal 2026 the company spent $175M buying back its own shares. Cash actually paid, from its cash-flow statement.
Stock since the trade +48.5% · S&P 500 +13.7% · to Oct 5
A board member of Haemonetics paid $99K out of pocket for Haemonetics shares. The Haemonetics shares held grew by 6%.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $49.55 on Oct 6, 2025 to $104.68 on Oct 5, 2026 (+111.3%). Disclosed activity in the last 12 months: 1 insider purchase, 0 insider sales, 0 Congress purchases, 0 Congress sales.
